( MENAFN - ACCESSWIRE) Nemysis is pleased to announce the further strengthening of its IP portfolio in relation to its unique and innovative nanoparticulate oral iron supplement, IHAT (Iron Hydroxide Adipate Tartrate), for the safe treatment of iron deficiency and iron deficiency anaemia. DUBLIN, IRELAND / ACCESSWIRE / May 23, 2024 / Nemysis is pleased to announce the further strengthening of its IP portfolio in relation to its unique and innovative nanoparticulate oral iron supplement, IHAT (Iron Hydroxide Adipate Tartrate), for the safe treatment of iron deficiency and iron deficiency anaemia. The new patent (WO2021204705) was recently granted in Europe for the use of IHAT in the treatment and prevention of iron deficiency in liver disease, for which it is perfectly suited due to experimental and toxicological evidence of no iron overload in the liver from orally supplemented IHAT.
This adds to the already robust Intellectual Property and Patent Protection of IHAT globally, including previous patents granted for other therapeutic uses, manufacturing and composition protection of IHAT and its development pipeline. Together, these patents recognise and provide robust protection for IHAT as a unique, innovative and safe oral iron supplement relative to all other existing oral iron supplements. Dr.
Cristina Comelli, Chief Scientific Officer, remarks: "This newly granted patent protects the use of IHAT for the safe treatment and iron repletion in individuals with anaemia and und.
